Progression and application of circulating tumor DNA in lymphoma
10.3760/cma.j.cn121090-20240528-00197
- VernacularTitle:循环肿瘤DNA在淋巴瘤中的进展和应用
- Author:
Dezhi HUANG
1
;
Xi ZHANG
;
Jun RAO
Author Information
1. 陆军军医大学第二附属医院血液病医学中心，全军临床重点专科，创伤与化学中毒国家重点实验室，重庆市医学重点学科，血液病与微环境重庆市重点实验室，重庆 400037
- From:
Chinese Journal of Hematology
2024;45(9):878-882
- CountryChina
- Language:Chinese
-
Abstract:
Lymphomas are a highly heterogeneous group of tumors that are classified into several subtypes. The gold standard method for the molecular profiling of lymphoma is based on invasive lymph node or tissue biopsy. However, this method cannot accurately capture spatial tumor heterogeneity in each patient as well as systemic tumor invasion and tumor burden. Circulating tumor DNA (ctDNA) is an emerging and highly versatile biomarker that overcomes the basic limitations of imaging scanning and tissue biopsy; has the characteristics of being simple, rapid, and non-invasive; and has good specificity and high sensitivity. ctDNA testing has been applied to a variety of subtypes of lymphoma and has been used for somatic mutation genotyping, efficacy monitoring during treatment, detection of minimal residual disease, and the prediction of survival, which may help clinicians make better clinical decisions in the diagnosis and treatment of lymphoma patients. Furthermore, this study also aims to review the different methods of ctDNA analysis and describe the specific applications of ctDNA in different lymphoma subtypes.
